Senzime Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 58

Employees

  • Stock Symbol
  • SEZI

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.32
  • (As of Thursday Closing)

Senzime General Information

Description

Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.

Contact Information

Website
www.senzime.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Verkstadsgatan 8, hus 1
  • 753 23 Uppsala
  • Sweden
Primary Industry
Monitoring Equipment
Stock Exchange
STO
Corporate Office
  • Verkstadsgatan 8, hus 1
  • 753 23 Uppsala
  • Sweden

Senzime Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Senzime Stock Performance

As of 19-Nov-2026, Senzime’s stock price is $0.32. Its current market cap is $50.9M with 157M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.32 $0.33 $0.24 - $0.65 $50.9M 157M 615K -$0.07

Senzime Financials Summary

As of 30-Sep-2026, Senzime has a trailing 12-month revenue of $11.3M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 41,833 82,388 63,702 83,199
Revenue 11,318 10,588 5,529 3,364
EBITDA (8,593) (11,648) (9,253) (10,997)
Net Income (10,430) (13,987) (11,226) (12,621)
Total Assets 31,576 40,326 38,643 43,380
Total Debt 2,096 1,523 2,054 1,147
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Senzime Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Senzime‘s full profile, request access.

Request a free trial

Senzime Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing a
Monitoring Equipment
Uppsala, Sweden
58 As of 2025

Amsterdam, Netherlands
 

Marseille, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Senzime Competitors (11)

One of Senzime’s 11 competitors is Philips, a Corporation company based in Amsterdam, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Philips Corporation Amsterdam, Netherlands
IDMed Formerly Accelerator/Incubator backed Marseille, France
Biomerieux Italia Corporation Bagno A Ripoli, Italy
GE HealthCare Technologies Corporation Chicago, IL
Medtronic Corporation Minneapolis, MN
You’re viewing 5 of 11 competitors. Get the full list »

Senzime Patents

Senzime Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260325032-A1 Electrode for robotic surgery Pending 18-Apr-2025
WO-2026221532-A1 Electrode system Pending 18-Apr-2025
EP-4704704-A1 Anesthetizing monitoring system, unit and method therefore Pending 26-Jun-2024
WO-2026005688-A1 Anesthetizing monitoring system, unit and method therefore Pending 26-Jun-2024
WO-2026005689-A1 Anesthetizing monitoring system, unit and method therefore Pending 26-Jun-2024 A61B5/4821
To view Senzime’s complete patent history, request access »

Senzime Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Senzime Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Senzime‘s full profile, request access.

Request a free trial

Senzime Acquisitions (3)

Senzime’s most recent deal was a Merger/Acquisition with Respiratory Motion for . The deal was made on 01-Jul-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Respiratory Motion 01-Jul-2022 Merger/Acquisition Monitoring Equipment
Acacia Designs 03-May-2016 Merger/Acquisition Monitoring Equipment
MD Biomedical 21-Apr-2015 Merger/Acquisition Other Healthcare Services
To view Senzime’s complete acquisitions history, request access »

Senzime ESG

Risk Overview

Risk Rating

Updated December, 31, 2022

18.2 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Technology Hardware

Industry

of 628

Rank

Percentile

Electronics Equipment

Subindustry

of 131

Rank

Percentile

To view Senzime’s complete esg history, request access »

Senzime Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
MD Biomedical Umeaa, Sweden 2010

Senzime FAQs

  • When was Senzime founded?

    Senzime was founded in 1999.

  • Where is Senzime headquartered?

    Senzime is headquartered in Uppsala, Sweden.

  • What is the size of Senzime?

    Senzime has 58 total employees.

  • What industry is Senzime in?

    Senzime’s primary industry is Monitoring Equipment.

  • Is Senzime a private or public company?

    Senzime is a Public company.

  • What is Senzime’s stock symbol?

    The ticker symbol for Senzime is SEZI.

  • What is the current stock price of Senzime?

    As of 19-Nov-2026 the stock price of Senzime is $0.32.

  • What is the current market cap of Senzime?

    The current market capitalization of Senzime is $50.9M.

  • What is Senzime’s current revenue?

    The trailing twelve month revenue for Senzime is $11.3M.

  • Who are Senzime’s competitors?

    Philips, IDMed, Biomerieux Italia, GE HealthCare Technologies, and Medtronic are some of the 11 competitors of Senzime.

  • What is Senzime’s annual earnings per share (EPS)?

    Senzime’s EPS for 12 months was -$0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process